Key result
Traditional and novel pharmacologic therapies, including cardiac myosin inhibitors and SGLT2 inhibitors, offer tailored treatment options for managing hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
This review summarizes the integration of traditional therapies, cardiac myosin inhibitors, and emerging metabolic and heart failure agents for the individualized management of hypertrophic cardiomyopathy.
This review highlights recent advances in hypertrophic cardiomyopathy (HCM) treatment, focusing on how to effectively implement both traditional and novel pharmacologic strategies in clinical practice. Traditional medications like beta-blockers and calcium channel blockers continue to play a critical role. However, new treatments, such as cardiac myosin inhibitors, provide an innovative approach for relieving symptoms, especially in obstructive HCM cases. Emerging therapies, including sodium-glucose cotransporter 2 inhibitors, sacubitril/valsartan, and ninerafaxstat, show promising benefits. Proper management of related conditions such as atrial fibrillation and heart failure is also essential. A comprehensive approach that considers individual patient characteristics and the specific subtype of HCM is essential for achieving optimal outcomes.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) conducted a review in Hypertrophic cardiomyopathy (HCM). Pharmacologic strategies (beta-blockers, calcium channel blockers, cardiac myosin inhibitors, SGLT2 inhibitors, sacubitril/valsartan, ninerafaxstat) was evaluated. Traditional and novel pharmacologic therapies, including cardiac myosin inhibitors and SGLT2 inhibitors, offer tailored treatment options for managing hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: